Deer Park, Illinois, based Eton Pharmaceuticals. Under the terms of the agreement, Dr. Reddy’s will pay $5 million upfront in cash, plus contingent payments of up to $45 million.
The acquisition supports Dr. Reddy’s efforts to accelerate and expand affordable medications for patients, the company said in a statement.
The portfolio includes the Biorphen (phenylephrine hydrocholoride) injection and Rezipres (ephedrine hydrochloride) injection NDAs (new drug application) with nine separate combinations of strengths and presentations and one first- to-file approved ANDA for Cysteine Hydrochloride for the US.
One strength each of Biorphen and Rezipres are currently commercially available in the U.S. The acquisition will complement Dr. Reddy’s U.S. institutional business with limited competition injectable products. The value of total addressable market for these products in the US is around $174 million for the calendar year ending in April 2022 according to IQVIA.
“Long before the COVID-19 pandemic, there have been concerns about access to some critical care products
for hospitals and health systems. This acquisition provides our North America organization with a foundational
footprint to help address products that are not always readily available for patients,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s. “For these and many other reasons, I believe we are well-positioned to integrate the portfolio and grow the business,” Kikuchi said.
